%0 Journal Article
%T Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system
%A Christina L. Aquilante
%A Deanna L. Kurz
%A Dylon Gregg
%A John C. Darnell
%A Paul B. Shaw
%A Samuel G. Johnson
%A Thomas Delate
%J Archive of "Pharmacy Practice".
%D 2017
%R 10.18549/PharmPract.2017.02.946
%X To assess the feasibility of clinical pharmacist-led CYP2C19 genotype-guided P2Y12 inhibitor antiplatelet drug therapy recommendations to cardiologists in an outpatient cardiology practice
%K Pharmacogenetics
%K Genetic Testing
%K Pharmacists
%K Patient Acceptance of Health Care
%K Platelet Aggregation Inhibitors
%K Acute Coronary Syndrome
%K Cytochrome P-450 CYP2C19
%K United States
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499354/